drugset / Trial / NCT01632917
Open-Label Pharmacokinetic Study of Final Formulations of ATX-101
RandomizedParallel-groupOpen-labelTreatment
Summary
The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to characterize the pharmacokinetic profile of the two ATX-101 formulations.
Timeline
- Start
- 2012-06
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATX-101 | Peptide | 10 mg/ml | Subcutaneous |
Indications
No indication recorded.